Skip to main content
Ondine Biomedical Inc. logo

Ondine Biomedical Inc. — Investor Relations & Filings

Ticker · OBI ISIN · CA68234M2058 LEI · 9845005B69E07CGF4A56 TSXV Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2025-06-10 Regulatory Filings
Country CA Canada
Listing TSXV OBI

About Ondine Biomedical Inc.

https://ondinebio.com/

Ondine Biomedical Inc. is a life sciences company that develops and commercializes photodisinfection-based therapies to prevent and treat a broad spectrum of infections, including those caused by drug-resistant pathogens. The company's patented platform technology involves applying a photosensitive agent to a targeted area, followed by illumination with non-thermal laser light. This process creates an oxidative burst that rapidly destroys pathogens like bacteria, viruses, and fungi without inducing microbial resistance. Its lead product, Steriwave™, is a nasal decolonization therapy used to eradicate pathogens in the nasal cavity, primarily to reduce the risk of healthcare-associated infections (HAIs) such as post-operative surgical site infections. The company's product pipeline is exploring applications for chronic rhinosinusitis, burns, wounds, and ventilator-associated pneumonia.

Recent filings

Filing Released Lang Actions
Ondine Presents Groundbreaking Findings
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service). It details scientific findings presented by Ondine Biomedical Inc. at a conference. Since it is a general corporate announcement regarding research and development progress that does not fit into specific categories like financial reports, dividends, or board changes, it falls under the 'Regulatory Filings' (RNS) category.
2025-06-10 English
Exercise of Options
Share Issue/Capital Change Classification · 100% confidence The document is an RNS announcement from Ondine Biomedical Inc. regarding the exercise of options and the subsequent issuance of 200,000 new ordinary shares. This falls under the category of share issuance or capital changes, which is specifically defined as 'Share Issue/Capital Change' (SHA).
2025-06-10 English
UCL Shows Steriwave Effective Against Mucor Fungus
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service). It announces research findings regarding the efficacy of the company's 'Steriwave' technology against a specific fungus. It does not fit into financial reporting categories like 10-K, IR, or ER, nor does it announce a corporate action like a dividend or share issue. As it is a general regulatory announcement regarding company operations and research, it falls under the RNS category.
2025-06-09 English
Canada's Largest Cardiac Centre Adopts Steriwave
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the London Stock Exchange's RNS (Reach) service. It announces a commercial update regarding the adoption of the company's product, Steriwave, by the University of Ottawa Heart Institute. As this is a general corporate announcement regarding business operations and does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a Regulatory Filing (RNS).
2025-06-05 English
Notice of AGM
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from Ondine Biomedical Inc. stating that the notice of the 2025 Annual General Meeting (AGM) and the associated form of proxy have been published on the company's website. It directs shareholders to the website to access these materials. Per the 'Menu vs Meal' rule, this is an announcement of a report/document rather than the proxy statement or AGM materials themselves, making it a Report Publication Announcement (RPA).
2025-06-04 English
2024 Full Year Results and Annual Report
Report Publication Announcement Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange. It explicitly states that it is announcing the '2024 Full Year Results and Annual Report' and provides a link to the actual PDF report. Per the 'Menu vs Meal' rule, since this is a short announcement (under 5,000 characters of core content) that directs the reader to an external link for the full report, it is classified as a Report Publication Announcement (RPA).
2025-05-15 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.